We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
176
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$578 0.02%
+24,500
New +$566K
SGEN
177
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$565 0.02%
176
-596
-77% -$20.8K
SGEN
178
DELISTED
Seagen Inc. Common Stock
SGEN
$558 0.02%
17,378
-34,669
-67% -$1.21M
OCGN icon
179
Ocugen
OCGN
$406M
$554 0.02%
+839
New +$554K
XOMA
180
PUT
DELISTED
Xoma
XOMA
$512 0.02%
71
+10
+16% +$857
PGNX
181
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$484 0.02%
+63,999
New +$383K
INSM icon
182
CALL
Insmed
INSM
$22.6B
$458 0.01%
+296
New +$4.2K
BMRN icon
183
BioMarin Pharmaceuticals
BMRN
$12B
$456 0.01%
+5,039
New +$419K
FOLD
184
CALL
DELISTED
Amicus Therapeutics
FOLD
$454 0.01%
+546
New +$3.75K
MDCO
185
PUT
DELISTED
Medicines Co
MDCO
$448 0.01%
162
+21
+15% +$520
ARIA
186
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$439 0.01%
63,888
-138,557
-68% -$867K
CVM.WS
187
DELISTED
Cel-Sci Corp Series S
CVM.WS
$438 0.01%
3,064,745
-907,692
-23% -$146K
HZNP
188
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$427 0.01%
331
+90
+37% +$1.13K
NBSE
189
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$417 0.01%
125
-73
-37% -$224K
ACHN
190
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$363 0.01%
296
-3,642
-92% -$44.5K
AGIO icon
191
PUT
Agios Pharmaceuticals
AGIO
$2.1B
$359 0.01%
+32
New +$2.86K
PCYC
192
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$355 0.01%
29
– –
KERX
193
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$354 0.01%
250
– –
SGYPW
194
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$336 0.01%
460,745
+74,354
+19% +$50.6K
ALKS icon
195
CALL
Alkermes
ALKS
$8.2B
$316 0.01%
54
-1,285
-96% -$65.5K
ALXA
196
CALL
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$304 0.01%
2,040
– –
EXEL icon
197
CALL
Exelixis
EXEL
$14.2B
$290 0.01%
2,014
-1,230
-38% -$1.92K
IPCI
198
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$286 0.01%
127
+58
+84% +$1.57K
CPXX
199
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$275 0.01%
140,234
+33,105
+31% +$68.7K
ITP icon
200
IT Tech Packaging
ITP
$2.86M
$265 0.01%
23,880
-79,441
-77% -$949K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.